Galleri demand rises, but price pressure bites
- Galleri volume grew 50% year over year in Q1 2026, up from 36% for full-year 2025.
- Screening revenue made up about 98% of Q1 2026 revenue, so GRAL is now mostly a one-test story.
- Average selling price fell 9% year over year in Q1 2026, worse than the 6% decline in 2025.
- The Medicare MCED law creates a U.S. coverage path, but the benefit starts in 2029 and still needs FDA approval.
- The NHS-Galleri trial missed its primary endpoint, which gives payors and regulators a harder question to answer.
- Samsung could help fund and expand the story, but the investment remains tied to CFIUS review risk.
Demand is ahead of price
GRAIL is trying to make Galleri a new kind of cancer screen. The pitch is simple: one blood test that looks for a shared cancer signal across more than 50 cancer types, then points to where that signal may have started. The hard part is proving that this test should be used broadly and paid for broadly.
The bull case got stronger in Q1 2026. Galleri sales volume grew 50% year over year, a step up from 36% growth for full-year 2025. Management tied the growth to more commercial activity, electronic health record integrations, digital health partnerships, and greater awareness after positive PATHFINDER 2 and SYMPLIFY study results.
The bear case got sharper too. Average selling price fell 9% year over year in Q1 2026, worse than the 6% decline in 2025. Some price pressure can happen as a test scales, but a near double-digit drop raises a real question: is GRAIL buying growth with lower prices, or is the market already forcing weaker unit economics?
The next year is about proof and cash. Investors need to see ASP stabilize, the Samsung investment close, FDA progress on the PMA filing, and the full NHS-Galleri data. The Medicare MCED law helps the long-term case, but coverage begins in 2029 and still depends on FDA approval and evidence that payors accept.
One test pays the bills
GRAIL makes most of its money by selling the Galleri test in the United States. Galleri is sold today as a Laboratory Developed Test, or LDT, which means it is offered through a lab pathway rather than as a fully FDA-approved medical device. Customers can come through primary care doctors, health systems, self-insured employers, digital health partners, and life insurance providers.
In Q1 2026, screening revenue was about 98% of total revenue. That makes the business simple to understand, but also highly concentrated. If Galleri adoption slows, pricing weakens, or regulators and payors push back, there is not a large second business to soften the hit.
A smaller development services business serves biopharma and clinical customers using GRAIL's methylation platform. That line was about 2% of Q1 2026 revenue and declined 65% year over year in the quarter. GRAIL has also cut back spending on other product programs so it can focus on Galleri commercialization and the PMA submission.
The long-term money path is reimbursement. Today, GRAIL is building demand before broad Medicare coverage. The Medicare MCED law creates a national coverage process for FDA-approved MCED tests, but the benefit starts in 2029. That timing matters because GRAIL may need more capital if cash burn stays high before coverage arrives.
Galleri, plus smaller options
Galleri
Galleri is the core product and the main revenue driver. It is a blood-based multi-cancer early detection test designed to detect a shared cancer signal across more than 50 cancer types and predict where the signal came from.
Galleri FDA PMA program
The PMA path is not a separate test, but it is central to the value of Galleri. FDA approval is needed for the broad reimbursement plan tied to the Medicare MCED law.
Research-use-only services
GRAIL offers research-use-only services to biopharma partners through its methylation platform. This is much smaller than screening revenue and is part of development services.
Development services
Development services revenue comes from biopharmaceutical and clinical customers. It made up about 2% of Q1 2026 revenue and fell 65% year over year in that quarter.
Diagnostic aid for cancer program
The diagnostic aid for cancer program is not the focus today. GRAIL has substantially decreased investment in this program to direct resources toward Galleri.
Minimal residual disease program
The minimal residual disease program has also been de-prioritized. It may retain future optional value, but the current company story is Galleri.
Revenue mix is concentrated
The segment mix is from Q1 2026. Screening revenue was about 98% of total revenue, so changes in Galleri volume or price can move the whole company.
What could break the thesis
ASP keeps falling
High impact · High oddsAverage selling price fell 9% year over year in Q1 2026, worse than the 6% decline in 2025. If that pace continues, strong volume growth may not turn into strong margins. Lower pricing could also raise future funding needs before Medicare coverage starts in 2029.
FDA approval slips or disappoints
High impact · Medium oddsGRAIL's broad U.S. reimbursement plan depends on FDA premarket approval for Galleri. The company filed the PMA in January 2026, but FDA feedback can still change timing, evidence needs, or labeling. A weaker label would limit the commercial upside even if approval arrives.
Clinical utility doubt after NHS result
High impact · Medium oddsThe NHS-Galleri trial showed a reduction in stage 4 cancer diagnoses, but it did not meet the primary endpoint for a statistically significant combined reduction in stage 3 and 4 cancers. That gives payors and regulators a reason to question whether Galleri improves outcomes enough to justify broad use. The full data presentation and NHS decision are key.
Samsung investment does not close
Medium impact · Medium oddsThe Samsung strategic investment could help liquidity and support expansion in Korea and possibly other Asian markets. It is still subject to conditions, including CFIUS review. If it fails or is delayed, GRAIL may have less room to fund growth before reimbursement.
MCED competition pressures price and share
Medium impact · High oddsExact Sciences and Guardant Health launched competing MCED products in 2025. New tests could pressure Galleri pricing, provider attention, and market share. This matters more now because GRAIL's ASP decline has already accelerated.
In one breath
What does GRAIL do?
GRAIL sells Galleri, a blood test that screens for a cancer signal across more than 50 cancer types. The company is focused on proving Galleri should be widely used and reimbursed.
Is Galleri FDA approved?
Galleri is currently sold in the United States as a Laboratory Developed Test. GRAIL filed a PMA in January 2026, and FDA approval is central to the Medicare coverage path.
Why does average selling price matter so much?
Average selling price shows how much GRAIL earns per Galleri test before costs. Volume grew 50% in Q1 2026, but ASP fell 9%, so investors need to know whether growth is coming at the cost of weaker economics.
What is the Medicare MCED law?
The law created a Medicare coverage benefit category for multi-cancer early detection tests. For GRAIL, the key point is that coverage starts in 2029 and depends on FDA approval and CMS review.